The Impact of Valve Flow Dynamics on Disease Regression and Outcomes After TAVR

 

 

  • Regression of LV Mass After TAVR Using a Novel Biomimetic Valve Design
    Amar Krishnaswamy, MD, recaps the latest data on flow patterns and LV mass regression with the DurAVR® Transcatheter Heart Valve
     
  • A New Era of TAVR Research
    Panelists discuss the potential impact Flow CMR could have on research into valve performance, durability, and patient outcomes
     
  • Restoration of Laminar Flow as a Promising Therapeutic Target
    Panelists explore the hypothesis that restoring healthy laminar flow may increase disease regression after TAVR
     

 

 

PANELISTS

Amar Krishnaswamy, MD  

Amar Krishnaswamy, MD
Cleveland Clinic
Cleveland, OH

 Nicolas Van Mieghem, MD  

Nicolas Van Mieghem, MD
Erasmus University Medical Center
Rotterdam, Netherlands
Bernard Prendergast, DM  

Bernard Prendergast, DM
Cleveland Clinic London
London, United Kingdom

      

 

This program was supported by:

 

 

Anteris-Logo